153 related articles for article (PubMed ID: 37668680)
1. Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients.
Abbaspour A; Dehghani M; Setayesh M; Tavakkoli M; Rostamipour HA; Ghorbani M; Ramzi M; Omidvari S; Moosavi F; Firuzi O
Cancer Chemother Pharmacol; 2023 Dec; 92(6):475-483. PubMed ID: 37668680
[TBL] [Abstract][Full Text] [Related]
2. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
[TBL] [Abstract][Full Text] [Related]
3. FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
Serdjebi C; Gagnière J; Desramé J; Fein F; Guimbaud R; François E; André T; Seitz JF; Montérymard C; Arsene D; Volet J; Abakar-Mahamat A; Lecomte T; Guerin-Meyer V; Legoux JL; Deplanque G; Guillet P; Ciccolini J; Lepage C; Dahan L
PLoS One; 2015; 10(8):e0135907. PubMed ID: 26308942
[TBL] [Abstract][Full Text] [Related]
4. Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
Tibaldi C; Camerini A; Tiseo M; Mazzoni F; Barbieri F; Vittimberga I; Brighenti M; Boni L; Baldini E; Gilli A; Honeywell R; Chartoire M; Peters GJ; Giovannetti E;
Br J Cancer; 2018 Nov; 119(11):1326-1331. PubMed ID: 30405211
[TBL] [Abstract][Full Text] [Related]
5. Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
Ding X; Chen W; Fan H; Zhu B
Gene; 2015 Mar; 559(1):31-7. PubMed ID: 25582275
[TBL] [Abstract][Full Text] [Related]
6. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies.
Ciccolini J; Dahan L; André N; Evrard A; Duluc M; Blesius A; Yang C; Giacometti S; Brunet C; Raynal C; Ortiz A; Frances N; Iliadis A; Duffaud F; Seitz JF; Mercier C
J Clin Oncol; 2010 Jan; 28(1):160-5. PubMed ID: 19933910
[TBL] [Abstract][Full Text] [Related]
7. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
Farrell JJ; Bae K; Wong J; Guha C; Dicker AP; Elsaleh H
Pharmacogenomics J; 2012 Oct; 12(5):395-403. PubMed ID: 21625252
[TBL] [Abstract][Full Text] [Related]
8. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
[TBL] [Abstract][Full Text] [Related]
9. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
Raynal C; Ciccolini J; Mercier C; Boyer JC; Polge A; Lallemant B; Mouzat K; Lumbroso S; Brouillet JP; Evrard A
Ther Drug Monit; 2010 Feb; 32(1):53-60. PubMed ID: 20010457
[TBL] [Abstract][Full Text] [Related]
10. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples.
Giovannetti E; Laan AC; Vasile E; Tibaldi C; Nannizzi S; Ricciardi S; Falcone A; Danesi R; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):720-5. PubMed ID: 18600531
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
12. Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines.
Bjånes TK; Jordheim LP; Schjøtt J; Kamceva T; Cros-Perrial E; Langer A; Ruiz de Garibay G; Kotopoulis S; McCormack E; Riedel B
Drug Metab Dispos; 2020 Mar; 48(3):153-158. PubMed ID: 31871136
[TBL] [Abstract][Full Text] [Related]
13. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Yonemori K; Ueno H; Okusaka T; Yamamoto N; Ikeda M; Saijo N; Yoshida T; Ishii H; Furuse J; Sugiyama E; Kim SR; Kikura-Hanajiri R; Hasegawa R; Saito Y; Ozawa S; Kaniwa N; Sawada J
Clin Cancer Res; 2005 Apr; 11(7):2620-4. PubMed ID: 15814642
[TBL] [Abstract][Full Text] [Related]
14. Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer.
Li J; Xu D; Huang J; Wang YN; Ma XP; Lin ZY; Gong P
Int J Biol Markers; 2019 Dec; 34(4):389-397. PubMed ID: 31603383
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
Shord SS; Patel SR
J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
[TBL] [Abstract][Full Text] [Related]
16. Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen.
Serdjebi C; Seitz JF; Ciccolini J; Duluc M; Norguet E; Fina F; Lacarelle B; Ouafik L; Dahan L
Pharmacogenomics; 2013 Jul; 14(9):1047-51. PubMed ID: 23837479
[TBL] [Abstract][Full Text] [Related]
17. The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis.
Li H; Wang X; Wang X
Int J Biol Markers; 2014; 29(3):e224-32. PubMed ID: 24557790
[TBL] [Abstract][Full Text] [Related]
18. Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment.
Peters GJ; Honeywell RJ; Maulandi M; Giovannetti E; Losekoot N; Etienne-Grimaldi MC; Milano G; Serdjebi C; Ciccolini J;
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):403-12. PubMed ID: 24940698
[TBL] [Abstract][Full Text] [Related]
19. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
[TBL] [Abstract][Full Text] [Related]
20. Cytidine deaminase activity increases in the blood of breast cancer patients.
Buhagiar-Labarchède G; Onclercq-Delic R; Vacher S; Berger F; Bièche I; Stoppa-Lyonnet D; Amor-Guéret M
Sci Rep; 2022 Aug; 12(1):14062. PubMed ID: 35982128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
